Assessment of Treatment Pattern for Management of Hyperphosphatemia in Maintenance Hemodialysis Patients: A Prospective Observational Comparative Study

Main Article Content

Anjitha Roy
Shaji George
Maria James
Edwin Antony

Abstract

Background: Hyperphosphatemia is a common complication of End-Stage Renal Disease (ESRD) associated with fluctuating serum levels of phosphorus, calcium, para thyroid hormone (PTH), and metastatic calcification. Based on the calcium-phosphorus level, patients may receive Calcium free or calcium-based drugs with phosphorus restricted diet.

Objective: To assess the treatment modalities for the management of hyperphosphatemia.

Methodology: A Prospective-observational-comparative-multivariate study, conducted in a tertiary care teaching hospital located in Ernakulam district of Kerala, in India for a period of 6 months. All patients admitted for Hemodialysis(HD) with ESRD and those aged  above 35 were included in the study based on pilot study. Baseline data were obtained at the study entry by utilizing a semi-structured questionnaire, followed by the laboratory values of phosphorus, calcium, inter dialytic weight gain (IDW), medications, etc. from their treatment record. The patient's adherence behaviour was evaluated by using the international disease-specific ESRD adherence questionnaire.

Results: Data from 53 cases indicates that, treatment given for management of hyperphosphatemia was not rational, not based on serum levels of calcium and phosphorus. The majority of the population prescribed with calcium-free phosphate binder-sevelamer and only 28% of the population is having controlled serum calcium and phosphorus levels. Poor economic status, a major factor contributing to the low adherence to the medications.

Conclusion: Socio-demographic factors statistically do not influence treatment patterns, but annual income correlates with poor drug adherence. For the management of hyperphosphatemia, sevelamer, and calcium-based calcium carbonate and/or calcium acetate were prescribed in this study population. Poor adherence to the diet was found to be the main cofounding factor for hyperphosphatemia.

Keywords:
Hyperphosphatemia, haemodialysis, hypercalcemia, adherence, phosphate binder.

Article Details

How to Cite
Roy, A., George, S., James, M., & Antony, E. (2020). Assessment of Treatment Pattern for Management of Hyperphosphatemia in Maintenance Hemodialysis Patients: A Prospective Observational Comparative Study. Asian Journal of Research in Nephrology, 3(2), 17-25. Retrieved from https://journalajrn.com/index.php/AJRN/article/view/30101
Section
Original Research Article

References

Levey AS, de Jong PE, Coresh J, Nahas ME l, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: A KDIGO controversies conference report. Kidney International [Internet]. Elsevier BV. 2011;80(1):17–28.

Naghibi M, Rajabi O, Hami M, et.al. Comparison of phosphate lowering properties of calcium acetate and calcium carbonate in hemodialysis patients. Iranian Journal of Pharmacology and Therapeutics. 2006;73-76.

Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). American Journal of Kidney Diseases [Internet]. Elsevier BV. 2008;52(3):519–30.

Nolan CR, Qunibi WY. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintance hemodialysis. Kidney International. 2005;67:S13-S20.

Coland JA. Control of hyperphosphatemia among patients with ESRD. Journal of American Society of Nephrology. 2005;16:S107-S114.

Covic A, Rastogi A. Hyperphosphatemia in patients with ESRD: Assessing the current evidence linking outcomes with treatment adherence. BMC Nephrology. 2013;14:1471-2369.

Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney International. 2007;72(9):1130-1137.

Rabbani SA, Sathvik BS, Rao PGM, Kurian MT, Essawy BEL. Hyper-phosphatemia in end stage renal disease: Prevalence and patients characteristics of multiethnic population of United Arab Emirates. International Journal of Pharmacy and Pharmaceutical Science. 2017;9:283-287.

Sgaman AM, Kowalski SR. Hyper-phosphatemia management in patients with chronic kidney disease. Saudi Pharmaceutical Journal. 2016;24(4):494-505.

Narayana SA, Balaubramanian T, Nathaliya PM, Hussain PN, Salim KTM, Lubab PM. A cross sectional study on assessment of health-related quality of life among end stage renal disease patients undergoing hemodialysis. Clinical Epidemiology and Global Health. 2017;5: 148-153.

Saif I, Halim A, Altaf A, Saif M, Khalid M, Ahmad D, Imran H. Comparison of calcium acetate with calcium carbonate as phosphate binder in patients on maintenance hemodialysis. Pub Med (cited on 22/03/2019). 2007;19:26-28.

Available:http://www.ncbi.nih.gov

Chiu Y-W, Teitelbaum I, Misra M, de leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. American Society of Nephrology. 2009;1089-1096.